Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
T he new weight-loss drugs Wegovy and Zepbound are in high demand, and the clamoring will only increase in coming years, ...
The Danish regulator on Monday issued two statements saying the country faced a shortage of the Wegovy Flextouch 1 mg ...
Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital ...